Sphingosine 1-phosphate receptor agonism impairs skin dendritic cell migration and homing to secondary lymphoid tissue: Association with prolonged allograft survival

Transplant Immunology

Volumn 20, Issue 1-2, 2008, Pages 88-94

  Lan, Yuk Yuen ^a,b   Tokita, Daisuke ^a   Wang, Zhiliang ^a   Wang, Hao Chen ^a   Zhan, Jianghua ^a   Brinkmann, Volker ^c   Thomson, Angus W ^a,d  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Dendritic cells; FTY720; Migration; Skin; T cells

Indexed keywords

CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; DRUG METABOLITE; FINGOLIMOD; FINGOLIMOD PHOSPHATE; HOMING RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SPHINGOSINE 1 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CELL FUNCTION; CELL HOMING; CELL MIGRATION; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DENDRITIC CELL; GRAFT SURVIVAL; LYMPH NODE; LYMPHOID TISSUE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD86; CELL MOVEMENT; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNOSUPPRESSIVE AGENTS; LANGERHANS CELLS; LYMPH NODES; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; PHOSPHORIC ACID ESTERS; PROPYLENE GLYCOLS; RECEPTORS, CCR7; RECEPTORS, LYSOSPHINGOLIPID; SKIN TRANSPLANTATION; SPHINGOSINE; TRANSPLANTATION, HOMOLOGOUS;

EID: 56049094570     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2008.07.004     Document Type: Article

References (58)

1. Yopp A.C., Ledgerwood L.G., Ochando J.C., and Bromberg J.S. Sphingosine 1-phosphate receptor modulators: a new class of immunosuppressants. Clin Transplant 20 6 (2006) 788-795
2. Brinkmann V., Davis M.D., Heise C.E., Albert R., Cottens S., Hof R., et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277 24 (2002) 21453-21457
3. Kiuchi M., Adachi K., Kohara T., Minoguchi M., Hanano T., Aoki Y., et al. Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanols. J Med Chem 43 15 (2000) 2946-2961
4. Kahan B.D. FTY720: from bench to bedside. Transplant Proc 36 2 Suppl (2004) 531S-543S
5. Pinschewer D.D., Ochsenbein A.F., Odermatt B., Brinkmann V., Hengartner H., and Zinkernagel R.M. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J Immunol 164 11 (2000) 5761-5770
6. Habicht A., Clarkson M.R., Yang J., Henderson J., Brinkmann V., Fernandes S., et al. Novel insights into the mechanism of action of FTY720 in a transgenic model of allograft rejection: implications for therapy of chronic rejection. J Immunol 176 1 (2006) 36-42
7. Budde K., Schmouder R., Brunkhorst R., Nashan B., Lucker P.W., Mayer T., et al. Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients. Am J Transplant 3 7 (2003) 846-854
8. Chiba K., Yanagawa Y., Masubuchi Y., Kataoka H., Kawaguchi T., Ohtsuki M., et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol 160 10 (1998) 5037-5044
9. Yanagawa Y., Sugahara K., Kataoka H., Kawaguchi T., Masubuchi Y., and Chiba K. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo. J Immunol 160 11 (1998) 5493-5499
10. Mandala S., Hajdu R., Bergstrom J., Quackenbush E., Xie J., Milligan J., et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296 5566 (2002) 346-349
11. Chiba K., Hoshino Y., Suzuki C., Masubuchi Y., Yanagawa Y., Ohtsuki M., et al. FTY720, a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats. Transplant Proc 28 2 (1996) 1056-1059
12. Hoshino Y., Suzuki C., Ohtsuki M., Masubuchi Y., Amano Y., and Chiba K. FTY720, a novel immunosuppressant possessing unique mechanisms. II. Long-term graft survival induction in rat heterotopic cardiac allografts and synergistic effect in combination with cyclosporine A. Transplant Proc 28 2 (1996) 1060-1061
13. Kawaguchi T., Hoshino Y., Rahman F., Amano Y., Higashi H., Kataoka H., et al. FTY720, a novel immunosuppressant possessing unique mechanisms. III. Synergistic prolongation of canine renal allograft survival in combination with cyclosporine A. Transplant Proc 28 2 (1996) 1062-1063
14. Schuurman H.J., Menninger K., Audet M., Kunkler A., Maurer C., Vedrine C., et al. Oral efficacy of the new immunomodulator FTY720 in cynomolgus monkey kidney allotransplantation, given alone or in combination with cyclosporine or RAD. Transplantation 74 7 (2002) 951-960
15. Kahan B.D., Karlix J.L., Ferguson R.M., Leichtman A.B., Mulgaonkar S., Gonwa T.A., et al. Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study. Transplantation 76 7 (2003) 1079-1084
16. Tedesco-Silva H., Mourad G., Kahan B.D., Boira J.G., Weimar W., Mulgaonkar S., et al. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 79 11 (2005) 1553-1560
17. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 115 1 (2007) 84-105
18. Rosen H., Sanna G., and Alfonso C. Egress: a receptor-regulated step in lymphocyte trafficking. Immunol Rev 195 (2003) 160-177
19. Srinivasan S., Wang F., Glavas S., Ott A., Hofmann F., Aktories K., et al. Rac and Cdc42 play distinct roles in regulating PI(3,4,5)P3 and polarity during neutrophil chemotaxis. J Cell Biol 160 3 (2003) 375-385
20. Burns S., Thrasher A.J., Blundell M.P., Machesky L., and Jones G.E. Configuration of human dendritic cell cytoskeleton by Rho GTPases, the WAS protein, and differentiation. Blood 98 4 (2001) 1142-1149
21. Rosen H., and Goetzl E.J. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat Rev Immunol 5 7 (2005) 560-570
22. Spiegel S., and Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 4 5 (2003) 397-407
23. Le Stunff H., Milstien S., and Spiegel S. Generation and metabolism of bioactive sphingosine-1-phosphate. J Cell Biochem 92 5 (2004) 882-899
24. Brinkmann V., Cyster J.G., and Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 4 7 (2004) 1019-1025
25. Matloubian M., Lo C.G., Cinamon G., Lesneski M.J., Xu Y., Brinkmann V., et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427 6972 (2004) 355-360
26. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 6673 (1998) 245-252
27. Steinman R.M. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9 (1991) 271-296
28. Coates P.T., and Thomson A.W. Dendritic cells, tolerance induction and transplant outcome. Am J Transplant 2 (2002) 299-307
29. Steinman R.M., Hawiger D., and Nussenzweig M.C. Tolerogenic dendritic cells. Annu Rev Immunol 21 (2003) 685-711
30. Morelli A.E., and Thomson A.W. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 7 8 (2007) 610-621
31. Idzko M., Panther E., Corinti S., Morelli A., Ferrari D., Herouy Y., et al. Sphingosine 1-phosphate induces chemotaxis of immature and modulates cytokine-release in mature human dendritic cells for emergence of Th2 immune responses. Faseb J 16 6 (2002) 625-627
32. Muller H., Hofer S., Kaneider N., et al. The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. Eur J Immunol 35 2 (2005) 533-545
33. Lan Y.Y., De Creus A., Colvin B.L., Neuwirt H., Mosheimer B., Mayer G., et al. The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo. Am J Transplant 5 11 (2005) 2649-2659
34. Idzko M., Hammad H., van Nimwegen M., Kool M., Muller T., Soullie T., et al. Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function. J Clin Invest 116 11 (2006) 2935-2944
35. Romani N., Holzmann S., Tripp C.H., Koch F., and Stoitzner P. Langerhans cells - dendritic cells of the epidermis. Apmis 111 7-8 (2003) 725-740
36. Stoitzner P., Pfaller K., Stossel H., and Romani N. A close-up view of migrating Langerhans cells in the skin. J Invest Dermatol 118 1 (2002) 117-125
37. O Connell P.J., Li W., Wang Z., Specht S.M., Logar A.J., and Thomson A.W. Immature and mature CD8alpha+ dendritic cells prolong the survival of vascularized heart allografts. J Immunol 168 1 (2002) 143-154
38. Morelli A.E., Zahorchak A.F., Larregina A.T., Colvin B.L., Logar A.J., Takayama T., et al. Cytokine production by mouse myeloid dendritic cells in relation to differentiation and terminal maturation induced by lipopolysaccharide or CD40 ligation. Blood 98 (2001) 1512-1523
39. Wang Z., Castellaneta A., De Creus A., Shufesky W.J., Morelli A.E., and Thomson A.W. Heart, but not skin allografts from donors lacking Flt3 ligand exhibit markedly prolonged survival time. J Immunol 172 10 (2004) 5924-5930
40. Eto M., Hackstein H., Kaneko K., Nomoto K., and Thomson A.W. Promotion of skin graft tolerance across MHC barriers by mobilization of dendritic cells in donor hemopoietic cell infusions. J Immunol 169 5 (2002) 2390-2396
41. Larsen C.P., Steinman R.M., Witmer-Pack M., Hankins D.F., Morris P.J., and Austyn J.M. Migration and maturation of Langerhans cells in skin transplants and explants. J Exp Med 172 5 (1990) 1483-1493
42. Maeda Y., Matsuyuki H., Shimano K., Kataoka H., Sugahara K., and Chiba K. Migration of CD4 T cells and dendritic cells toward sphingosine 1-phosphate (S1P) is mediated by different receptor subtypes: S1P regulates the functions of murine mature dendritic cells via S1P receptor type 3. J Immunol 178 6 (2007) 3437-3446
43. Larsen C.P., Morris P.J., and Austyn J.M. Migration of dendritic leukocytes from cardiac allografts into host spleens. A novel pathway for initiation of rejection. J Exp Med 171 1 (1990) 307-314
44. Ohl L., Mohaupt M., Czeloth N., Hintzen G., Kiafard Z., Zwirner J., et al. CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity 21 2 (2004) 279-288
45. Czeloth N., Bernhardt G., Hofmann F., Genth H., and Forster R. Sphingosine-1-phosphate mediates migration of mature dendritic cells. J Immunol 175 5 (2005) 2960-2967
46. Allende M.L., Dreier J.L., Mandala S., and Proia R.L. Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration. J Biol Chem 279 15 (2004) 15396-15401
47. Sawicka E., Dubois G., Jarai G., Edwards M., Thomas M., Nicholls A., et al. The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity. J Immunol 175 12 (2005) 7973-7980
48. Radeke H.H., von Wenckstern H., Stoidtner K., Sauer B., Hammer S., and Kleuser B. Overlapping signaling pathways of sphingosine 1-phosphate and TGF-beta in the murine Langerhans cell line XS52. J Immunol 174 5 (2005) 2778-2786
49. Benvenuti F., Hugues S., Walmsley M., Ruf S., Fetler L., Popoff M., et al. Requirement of Rac1 and Rac2 expression by mature dendritic cells for T cell priming. Science 305 5687 (2004) 1150-1153
50. Lakkis F.G., Arakelov A., Konieczny B.T., and Inoue Y. Immunologic 'ignorance' of vascularized organ transplants in the absence of secondary lymphoid tissue. Nat Med 6 6 (2000) 686-688
51. Yopp A.C., Fu S., Honig S.M., Randolph G.J., Ding Y., Krieger N.R., et al. FTY720-enhanced T cell homing is dependent on CCR2, CCR5, CCR7, and CXCR4: evidence for distinct chemokine compartments. J Immunol 173 2 (2004) 855-865
52. Henning P., Ohl L., Junt T., Reiterer P., Brinkmann V., Nakano H., et al. CC chemokine receptor 7-dependent and -independent pathways for lymphocyte homing: modulation by FTY720. J Exp Med 194 12 (2001) 1875-1881
53. Honig S.M., Fu S., Mao X., et al. FTY720 stimulates multidrug transporter- and cysteinyl leukotriene-dependent T cell chemotaxis to lymph nodes. J Clin Invest 111 5 (2003) 627-637
54. Robbiani D.F., Finch R.A., Jager D., Muller W.A., Sartorelli A.C., and Randolph G.J. The leukotriene C(4) transporter MRP1 regulates CCL19 (MIP-3beta, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell 103 5 (2000) 757-768
55. Randolph G.J., Beaulieu S., Pope M., Sugawara I., Hoffman L., Steinman R.M., et al. A physiologic function for p-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels. Proc Natl Acad Sci U S A 95 12 (1998) 6924-6929
56. Pan S., Mi Y., Pally C., Sugawara I., Hoffman L., Steinman R.M., et al. A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. Chem Biol 13 11 (2006) 1227-1234
57. Brown B.A., Kantesaria P.P., and McDevitt L.M. Fingolimod: a novel immunosuppressant for multiple sclerosis. Ann Pharmacother 41 10 (2007) 1660-1668
58. Vachal P., Toth L.M., Hale J.J., Yan L., Mills S.G., Chrebet G.L., et al. Highly selective and potent agonists of sphingosine-1-phosphate 1 (S1P1) receptor. Bioorg Med Chem Lett 16 14 (2006) 3684-3687